A broad effect of ocrelizumab on the peripheral immune component in patients with early relapsing-remitting multiple sclerosis

被引：0
作者：
Garcia, A. [1 ]
Morille, J. [1 ]
Shah, S. [1 ]
Le Frere, F. [2 ]
Nicot, A. [1 ]
Berthelot, L. [1 ]
Wiertlewski, S. [1 ,2 ]
Gourraud, P. -A. [1 ,3 ]
Raposo, C. [4 ]
Bakdache, F. [4 ]
Buffels, R. [4 ]
Laplaud, D. -A. [1 ,2 ]
机构：
[1] Univ Nantes, CHU Nantes, INSERM, Ctr Rech Transplantat & Immunol,UMR 1064, Nantes, France
[2] CHU Nantes, Dept Neurol, CIC Neurol, Nantes, France
[3] CHU Nantes, INSERM, CIC 1413, Pole Hosp Univ 11 Sante Publ,Clin Donnees,ATIP Av, Nantes, France
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P701
引用
收藏
页码：593 / 594
页数：2
相关论文
共 50 条
  • [21] Comparing the Efficacy and Safety of Natalizumab and Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis and Spinal Lesions
    Huntemann, Niklas
    Mueller, Marc
    Masanneck, Lars
    Baumgart, Romy
    Axhausen, Franziska
    Wolff, Stephanie
    Kutsojannis, Bela
    Koelsche, Tristan
    Korsen, Melanie
    Pfeuffer, Steffen
    Meuth, Sven
    Pawlitzki, Marc
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 90 - 91
  • [22] Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study
    de Antonio, Luis A. Rodriguez
    Cuberta-Gonzalez, Ines
    Garcia-Castanon, Inmaculada
    Oreja-Guevara, Celia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 69
  • [23] Assessment of the lymphocyte repertoire in relapsing-remitting multiple sclerosis patients treated with ocrelizumab: the ImmunoReMS study
    Esposito, Federica
    Ferre, Laura
    Mascia, Elisabetta
    Sorosina, Melissa
    Clarelli, Ferdinando
    Santoro, Silvia
    Giordano, Antonino
    Cannizzaro, Miryam
    Moiola, Lucia
    Martinelli, Vittorio
    Filippi, Massimo
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 815 - 815
  • [24] Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis
    Putzki, N.
    Fischer, J.
    Gottwald, K.
    Reifschneider, G.
    Ries, S.
    Siever, A.
    Hoffmann, F.
    Kaefferlein, W.
    Kausch, U.
    Liedtke, M.
    Kirchmeier, J.
    Gmuend, S.
    Richter, A.
    Schicklmaier, P.
    Niemczyk, G.
    Wernsdoerfer, C.
    Hartung, H. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (06) : 713 - 720
  • [25] Cognitive deficits in early relapsing-remitting multiple sclerosis
    Tinnefeld, M.
    Wilhelm, H.
    Daum, I.
    Faustmann, P. M.
    Haase, C. G.
    AKTUELLE NEUROLOGIE, 2008, 35 (01) : 2 - 7
  • [26] Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients
    Arisi, Ivan
    Malimpensa, Leonardo
    Manzini, Valeria
    Brandi, Rossella
    di Sturmeck, Tommaso Gosetti
    D'Amelio, Chiara
    Crisafulli, Sebastiano
    Ferrazzano, Gina
    Belvisi, Daniele
    Malerba, Francesca
    Florio, Rita
    Pascale, Esterina
    Soreq, Hermona
    Salvetti, Marco
    Cattaneo, Antonino
    D'Onofrio, Mara
    Conte, Antonella
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [27] Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis
    Urshansky, Nataly
    Mausner-Fainberg, Karin
    Auriel, Eitan
    Regev, Keren
    Bornstein, Natan M.
    Karni, Arnon
    JOURNAL OF NEUROIMMUNOLOGY, 2011, 232 (1-2) : 171 - 178
  • [28] The Effect of Rituximab on the Cognitive Function of Patients with Relapsing-Remitting Multiple Sclerosis
    Najafi, Masood
    Farahmand, Ghasem
    Balali, Pargol
    Behkar, Atefeh
    Shahbazi, Mojtaba
    Moradian, Negar
    Pouyanmanouchehri, Sara
    Harirchian, Mohammad Hossein
    Ranji, Sara
    CLINICAL THERAPEUTICS, 2024, 46 (10) : e1 - e5
  • [29] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
    Agiela, Mabroka I. M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [30] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Izquierdo, Guillermo
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Yamout, Bassem I.
    Khoury, Samia
    Van Pesch, Vincent
    Macdonell, Richard
    Sa, Maria Jose
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Al-Asmi, Abdullah
    Robertson, Neil
    Coles, Alasdair
    Brown, J. William L.
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 629 - 631
12345